Study guide
Genomic, Genetic Testing, and Biomarker Literacy
OCN Oncology Certified Nurse Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: OCN Exam Orientation and Official Source Control
Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness
2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care
Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures
3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment
Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation
4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards
Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development
5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy
Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation
6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents
Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation
7 Chapter 7: Symptom Management and Supportive Care
Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination
8 Chapter 8: Oncologic Emergencies and Rapid Escalation
Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage
9 Chapter 9: Psychosocial Dimensions of Oncology Care
Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals
10 Chapter 10: Mixed OCN Case Labs
New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab
11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness
Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning
Genomic, Genetic Testing, and Biomarker Literacy
Key Takeaways Explain This Topic AI
Genomic (somatic) tumor testing evaluates acquired alterations in cancer tissue; genetic (germline) testing evaluates inherited variants present in normal cells with family implications.
Immunohistochemistry, fluorescence in situ hybridization, polymerase chain reaction, next-generation sequencing, and liquid biopsy answer different questions and have different limitations.
Biomarkers may be diagnostic, predictive, prognostic, pharmacogenomic, or monitoring tools; predictive markers estimate benefit, not a guarantee of response.
Nurses reinforce preparation, specimen needs, consent logistics, and follow-up while never independently classifying variants or selecting therapy.
A variant of uncertain significance (VUS) is not acted upon like a known pathogenic variant for surgery or cascade testing decisions.
Last updated: June 2026
- Genomic, Genetic Testing, and Biomarker Literacy
- The Core Distinction Patients Confuse
OCN candidates must separate two terms patients use interchangeably. Genomic (somatic) tumor testing evaluates alterations in cancer tissue or circulating tumor DNA that the tumor acquired — they are not in the patient's normal cells and are not inherited. Genetic (germline) testing evaluates inherited variants present in every normal cell and shared with relatives. A tumor BRCA1 finding on a somatic panel may or may not be germline; confirmatory germline testing is needed when criteria are met. The wording matters because implications for therapy, screening, insurance, and family communication differ.
The Genetic Information Nondiscrimination Act (GINA, 2008) bars health insurers and employers from using germline results discriminatorily, but it does not cover life, disability, or long-term-care insurance — a frequent patient question.
Common Test Methods
Test method What it detects Nursing point
Immunohistochemistry (IHC) Protein expression: ER, PR, HER2, mismatch-repair proteins, PD-L1 May guide therapy or trigger reflex testing
Fluorescence in situ hybridization (FISH) Gene amplification or rearrangement: HER2, ALK Needs adequate tissue and correct handling
Polymerase chain reaction (PCR) Known mutation or small variant set Fast but narrow breadth
Next-generation sequencing (NGS) Broad DNA/RNA panel: mutations, fusions, copy number, TMB, MSI Identifies targets, resistance, trial matches
Liquid biopsy Circulating tumor DNA from blood Useful when tissue is limited; a negative result may not exclude a target
High-Yield Biomarker-Drug Pairings
The OCN exam rewards recognition of biomarker-targeted therapy links:
HER2-positive breast/gastric cancer -> trastuzumab, pertuzumab (predictive).
EGFR mutation in non-small cell lung cancer -> osimertinib; ALK or ROS1 fusion -> targeted inhibitors.
BRAF V600E melanoma -> BRAF/MEK inhibitors.
Microsatellite-instability-high (MSI-H) / mismatch-repair-deficient (dMMR) tumors -> checkpoint inhibitors across cancer types.
BRCA1/2 mutation in ovarian, breast, prostate, pancreatic cancer -> PARP (poly ADP-ribose polymerase) inhibitors.
Biomarker Purposes
Biomarkers fall into five categories. Diagnostic confirms a cancer subtype. Predictive estimates likelihood of benefit from a specific drug (HER2 overexpression predicting trastuzumab benefit). Prognostic describes disease course regardless of therapy (Oncotype DX recurrence score in breast cancer). Pharmacogenomic flags metabolism or toxicity risk — for example, dihydropyrimidine dehydrogenase (DPYD) variants increase fluorouracil toxicity, and UGT1A1 affects irinotecan. Monitoring markers track response or resistance, such as serial circulating tumor DNA.
Nurses never say a biomarker guarantees response; it identifies likely options.
Germline Testing and Family Implications
Inherited pathogenic variants raise risk for specific cancers depending on the syndrome. High-yield examples:
- Gene / syndrome Associated cancers
- BRCA1 / BRCA2 (hereditary breast-ovarian) Breast, ovarian, prostate, pancreatic
- Mismatch-repair genes (Lynch syndrome) Colorectal, endometrial, gastric, ovarian, urinary
- APC (familial adenomatous polyposis) Colorectal (hundreds of polyps)
- TP53 (Li-Fraumeni) Sarcoma, breast, brain, adrenal, leukemia
- CDH1 Diffuse gastric, lobular breast
- RET (MEN2) Medullary thyroid, pheochromocytoma
Family-history red flags that warrant genetics referral: cancer at unusually young age, multiple relatives with related cancers, bilateral or multifocal disease, male breast cancer, ovarian or pancreatic cancer, metastatic prostate cancer, medullary thyroid cancer, numerous colon polyps, or a known familial variant. The OCN collects a three-generation pedigree when appropriate and refers; the nurse does not interpret inheritance for relatives.
Specimen and Result Literacy
Testing can fail. Decalcified bone, low tumor purity, scant tissue, old specimens, or prolonged formalin fixation degrade DNA. Liquid biopsy helps when tissue is inaccessible, but false negatives occur when tumor DNA shedding is low. Results are reported as pathogenic, likely pathogenic, variant of uncertain significance (VUS) , benign, or insufficient sample. A VUS is not treated like a pathogenic variant — no prophylactic surgery or cascade testing is driven by a VUS until reclassified. Nurses teach patients not to overinterpret a portal result before provider or genetics review.
Hereditary Syndrome Counseling and Cascade Testing
When a pathogenic germline variant is confirmed, cascade testing offers single-site testing to at-risk relatives, who can then pursue enhanced surveillance or risk reduction. For example, a confirmed Lynch syndrome variant prompts earlier and more frequent colonoscopy and consideration of endometrial surveillance; a BRCA1/2 carrier may discuss earlier mammography and breast MRI, risk-reducing salpingo-oophorectomy, and chemoprevention.
The OCN reinforces that these are decisions made with a genetics professional and provider, supports the patient's autonomy in choosing whether and when to inform relatives, and addresses anxiety, guilt, and confidentiality concerns. The nurse never directly informs relatives of their risk or recommends prophylactic surgery; that is the role of genetic counseling and the care team.
RN Scope and Coordination
Within scope: explain test purpose, collection, result timing, why results change planning, and whom to call. Outside scope: classifying variants, recommending prophylactic surgery, selecting targeted therapy, or telling relatives they carry risk. The OCN coordinates outside pathology blocks, confirms whether testing was already done, tracks pending results to prevent treatment delays, and escalates when family history meets referral criteria or a patient misunderstands germline implications.
A common test trap: a tumor-only (somatic) panel is not the same as germline testing, so a patient cannot assume children are affected based on a tumor result, and a benign or VUS germline result does not justify altering screening for relatives until reclassification occurs.